(Q37808304)

23 August 2017

title

Prostate cancer around the world. An overview (English)

1 reference

23 August 2017

1 reference

Fritz H Schröder

1

1 reference

23 August 2017

publication date

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

663-667

1 reference

Measurement of Prostate-Specific Antigen as a Screening Test for Prostate Cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Recent trends in prostate cancer mortality show a continuous decrease in several countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Quantifying the role of PSA screening in the US prostate cancer mortality decline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Changing demography of prostate cancer in Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Screening for prostate cancer appears to work, but at what cost?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Adjusting for non-compliance and contamination in randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.12.013

10.1016/J.UROLONC.2009.12.013

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference